Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Glioblastoma 10Astrocytoma 9Glioma 8Brain Neoplasms 7Oligodendroglioma 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 2Gliosarcoma 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Flucytosine × Clear all
NCT01562626 2021-05-12

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Anaeropharma Science, Inc.

Phase 1/2 Suspended
75 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡